Product Information

Expression Host	CHO cells
QC Testing Purity	> 90 % as determined by SDS-PAGE
Purification	Protein A purified from cell culture supernatant
Endotoxin Level	< 0.1 EU per μg of the protein as determined by the LAL method
Formulation	Supplied as a 0.22μm filtered solution in PBS, PH 7.4.
Stability & Storage	24 months at 2℃ to 8℃. Avoid repeated freeze-thaw cycles.

Background

CD20 is a specific signature molecule on the surface of B lymphocytes and is expressed on more than 95% of normal or malignant B lymphocytes. There is no expression of CD20 antigen in hematopoietic stem cells, progenitor cells, and other normal tissues. It consists of 297 amino acids with a molecular weight of 33 kD. CD20 has no internalization or cell surface shedding after binding with anti-CD20 mAb, which is an ideal antigen in the treatdment of B lymphocyte-related diseases. Anti-CD20 mAb can kill most of the lymphoma cells expressing CD20 molecules and normal B cells. Innate normal B cells are not affected by anti-CD20 mAb and can reconstruct B cell population. Therefore, anti-CD20 monoclonal antibodies are increasingly used in the treatment of B cell-related diseases.

References

Macardle PJ, Nicholson IC (2003). "CD20". J. Biol. Regul. Homeost. Agents 16 (2): 136–8.PMID 12144126.
Tamayose K, Sato N, Ando J; et al. (2002). "CD3-negative, CD20-positive T-cell prolymphocytic leukemia: case report and review of the literature". Am. J. Hematol. 71 (4): 331–5. doi:10.1002/ajh.10224. PMID 12447967.
Küster H, Zhang L, Brini AT; et al. (1992). "The gene and cDNA for the human high affinity immunoglobulin E receptor beta chain and expression of the complete human receptor". J. Biol. Chem. 267 (18): 12782–7. PMID 1535625.

Document

Anti-Human CD20 mAb

Anti-Human CD20 mAb_SDS

Anti-Human CD20 mAb-T&L